This study examines the trends in fluoroquinolone use in a tertiary-care hospital in Italy from 2015 to 2024, with a focus on the impact of European Medicines Agency (EMA) regulatory measures introduced in 2019. Analysing antimicrobial consumption data, the research found a significant overall reduction of 58% in fluoroquinolone use over the decade, with a marked decline of approximately 54.5% between 2019 and 2024 following EMA warnings and restrictions. Linear regression analysis demonstrated a strong downward trend in prescribing, likely influenced by hospital-level interventions such as personalized prescription protocols and electronic prescribing tools. Additionally, resistance rates among key pathogens, including E. coli and K. pneumoniae, decreased significantly during this period. These findings suggest that regulatory actions, combined with targeted hospital strategies, effectively reduced fluoroquinolone consumption, potentially contributing to improved antimicrobial stewardship and resistance patterns. Further research is warranted to assess how the observed decline in fluoroquinolone use translates to patient outcomes and whether replacement therapies are being used judiciously.
- Open Access
- Communication
The Decline of Fluoroquinolones Use in Clinics: 2015–2024 Data from an Italian Tertiary-Care Hospital
- Giacomo Bertolino 1,
- Melania Rivano 1,
- Valentina Mureddu 1, *,
- Silvia Vargiu 2,
- Roberto Francesco Mura 2,
- Arianna Cadeddu 1
Author Information
Received: 27 Jun 2025 | Revised: 13 Oct 2025 | Accepted: 20 Oct 2025 | Published: 07 Nov 2025
Abstract
Keywords
quinolones | antimicrobial consumption | fluoroquinolones | regulatory interventions | EMA | European medicines agency | hospital prescribing trends
References
- 1.Kim, E.S.; Hooper, D.C. Clinical Importance and Epidemiology of Quinolone Resistance. Infect. Chemother. 2014, 46, 226–238. https://doi.org/10.3947/ic.2014.46.4.226.
- 2.Jonville-Béra, A.-P.; Largeau, B.; di Meglio, F.; et al. The Safety Profile of Fluoroquinolones. Infect. Dis. Now 2025, 55, 105064. https://doi.org/10.1016/j.idnow.2025.105064.
- 3.European Medicines Agency. Fluoroquinolone and Quinolone Antibiotics: PRAC Recommends Restrictions on Use; EMA/668915/2018; European Medicines Agency: Amsterdam, The Netherlands, 2018.
- 4.Fluoroquinolone Antibiotics: Reminder of Measures to Reduce the Risk of Long-Lasting, Disabling and Potentially Irreversible Side Effects. European Medicines Agency (EMA). Available online: https://www.ema.europa.eu/en/news/fluoroquinolone-antibiotics-reminder-measures-reduce-risk-long-lasting-disabling-potentially-irreversible-side-effects (accessed on 11 August 2025).
- 5.Ly, N.F.; Flach, C.; Lysen, T.S.; et al. Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing Trends. Drug Saf. 2023, 46, 405–416. https://doi.org/10.1007/s40264-023-01286-4.
- 6.Osservatorio Nazionale Sull’impiego dei Medicinali. L’uso Degli Antibiotici in Italia. Rapporto Nazionale 2023. Roma: Agenzia Italiana del Farmaco, 2025. The Medicines Utilisation Monitoring Centre. National Report on Antibiotics Use in Italy. 2023; Italian Medicines Agency: Rome, 2025. ISBN 979-12-80335-60-9.
- 7.Antimicrobial Consumption in the EU/EEA (ESAC-net)–Annual Epidemiological Report for 2023. European Centre for Disease Prevention and Control. Available online: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-consumption-eueea-esac-net-annual-epidemiological-report-2023 (accessed on 11 August 2025).
- 8.Cizman, M.; Beovic, B. Antibiotic Hospital Consumption Expressed in Defined Daily Doses (DDD)/100 Bed-Days. Infection 2014, 42, 223–224. https://doi.org/10.1007/s15010-013-0537-5.
- 9.IBM SPSS Statistics 29.0.2.0. Ibm.com. Available online: https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-29020 (accessed on 11 August 2025).
- 10.Bertolino, G.; Marras, L.; Mureddu, V.; et al. Trends of Antimicrobial Consumption in Hospital: Tackling the Hidden Part of the Iceberg with an Electronic Personalised Prescription Software for Antimicrobial Stewardship. Adv. Exp. Med. Biol. 2023, 1370, 113–123. https://doi.org/10.1007/5584_2022_752.
- 11.Cosa Sapere Sugli Antibiotici Fluorochinolonici. Gov.it. Available online: https://www.aifa.gov.it/-/cosa-sapere-sugli-antibiotici-fluorochinolonici (accessed on 11 August 2025).
How to Cite
Bertolino, G.; Rivano, M.; Mureddu, V.; Vargiu, S.; Mura, R. F.; Cadeddu, A. The Decline of Fluoroquinolones Use in Clinics: 2015–2024 Data from an Italian Tertiary-Care Hospital. Journal of Microbes in Health and Disease 2025, 1 (1), 100005. https://doi.org/10.53941/jmhd.2025.100005.
RIS
BibTex
Copyright & License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Contents
References
Suite 4002 Level 4, 447 Collins Street, Melbourne, Victoria 3000, Australia
General Inquiries: info@sciltp.com